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Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) affect 25% of the world population. NAFLD is predicted to soon become the main cause of liver morbidity
and transplantation. The disease is characterized by a progressive increase of lipid accumulation in hepatocytes, which eventually induce fibrosis and inflammation, and can ultimately cause cirrhosis and hepatic
carcinoma. Here, we created a patterned model of NAFLD on a chip using free fatty acid gradients to recapitulate a spectrum of disease conditions in a single continuous liver tissue. We established the NAFLD progression via quantification of intracellular lipid accumulation and transcriptional levels of fatty acid transporters and NAFLD pathogenesis markers. We then used this platform to create oxygen driven steatosis
zonation mimicking the sinusoidal lipid distribution on a single continuous tissue and showed that this fat
zonation disappears under progressed steatosis, in agreement with in vivo observations and recent computational studies. While we focus on free fatty acids and oxygen as the drivers of NAFLD, the microfluidic
platform here is extensible to simultaneous use of other drivers.

Introduction
Non-alcoholic fatty liver disease (NAFLD)1 is a growing epidemic worldwide in part due to obesity and insulin resistance
leading to liver accumulation of triglycerides and free fatty
acids;2 and is now the leading cause of chronic liver disease
in the USA and Europe3,4 and the second most common reason for liver transplantation.2,5 The prevalence of NAFLD
stands at 20–30% in Western countries and the overall world
prevalence is estimated to be at 20–25%.3,4,6,7 The prevalence
amongst obese or diabetic patients is even higher, ∼75% for
Western countries and 40–90% worldwide.4 Considering the
rise of unhealthy diets and the growing patient population
with obesity and diabetes, NAFLD is projected to become the
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leading cause of liver morbidity and mortality, and liver transplantation in the next 20 years.2,8 The current financial burden of NAFLD, with all incident and prevalent cases, is estimated at slightly over $100 billion in the United States.3,9
There are currently no FDA approved therapeutics for NAFLD
treatment,7 and the NASH drug market is expected to grow
from $1 billion in 2015 to $25 billion till 2025.10 Accordingly,
developing a progressive disease model and a highthroughput testing platform for NAFLD/NASH is crucial.
The past decade has resulted in numerous studies on the
development of in vitro NAFLD models owing to the overwhelming increase in NAFLD cases. In general most of these
in vitro models were limited due to: a) use of cell lines that
do not properly recapitulate the lipid and carbohydrate metabolisms, b) use of supraphysiological levels of glucose and
insulin along with other media components, c) lack of perfusion (i.e. static models) resulting in incorrect chemical kinetics, d) models focusing only a specific phase of the disease,
and e) low-throughput.11–17 Among these models, a few stand
out despite their shortcomings. For example, Davidson et al.
established a stable static long-term culture approach with
primary hepatocyte and fibroblast co-cultures (a micropatterned co-culture system) where they studied effects of
chronic hypo- and hyperglycemia; however, this study was
limited by lack of flow.11 A study which featured a continuous flow with physiologic glucose and insulin levels was
conducted by Feaver et al., where multiple cell types were co-

cultured in the HemoShear system.18 This platform was used
to create a lipotoxic model via the administration of a cocktail of free fatty acids; it was limited in its throughput
allowing one experimental condition per device.18 Since gut
plays an important role in NAFLD pathogenesis, Lee et al. developed a gut-liver model studying the interactions among
these systems, but was limited by its low-throughput and use
of a cell line instead of primary hepatocytes.12
Here we aimed to create an in vitro platform that can recapitulate different aspects of NAFLD progression and its
drivers – such as exposure to free fatty acids and oxygen deprivation – where these drivers can be studied at multiple concentrations on a single microfluidic chip, a single continuous
liver tissue under perfusion. This progressive fatty liver disease platform is based on our recent Metabolic Patterning on
a Chip (MPOC) platform that takes advantage of enforced
microfluidic gradients to enable gradual patterning of different metabolic activities for cells cultured across the length of
a microfluidic device.19 We have previously used this platform to recapitulate metabolic liver zonation in both rat and
human primary hepatocytes using hormones, inducers and
oxygen gradients.19,20 This approach can be used to study either a) the progression of NAFLD spectrum or b) the spatial
physiological heterogeneity, i.e. zonal lipid accumulation21
and other heterogeneity22 observed during the disease, on a
single integrated microfluidic chip. This approach results in
reduced resource and pumping requirements compared to
multiple well plate culture or multiple individual chip
experiments.
NAFLD is a progressive disease in its pathogenesis and
has multiple stages with different levels of fat accumulation,
inflammation and cellular injury among others. Here, in the
first part of our study, we captured the progressive nature of
this disease in its fat accumulation aspect. We created patterned disease physiologies of different severity similar to the
wide spectrum of cellular conditions in NAFLD. These
in vitro physiologies that we create can simulate either the
spatial heterogeneity and/or the progression of the disease.
Specifically, we quantified the fat accumulation in primary
rat hepatocytes upon exposure to a gradient of free fatty acids
(FFA) and then confirmed the establishment of a progressive
disease model via assessing the changes in expression levels
of markers related to NAFLD and lipid metabolism.
The metabolic zonation of the liver – changes in metabolic
activity across the liver sinusoid in response to dynamic concentration gradients and genetic drivers – is also found to be
important in NAFLD pathogenesis. Specifically, triglyceride
(TG) accumulation in the liver has predominantly been observed in hepatocytes in the pericentral zone for patients with
NAFLD or NASH23,24 and this has been primarily attributed
to the gradual decrease in oxygen availability in the liver sinusoid.25,26 Accordingly, in the second part of this study, we
investigated the effects of oxygen zonation on fat accumulation. While different in vitro oxygen zonation systems have
been developed, none have established or measured its effect
in intracellular lipid accumulation.27,28 Here, we established

an oxygen gradient in our microfluidic platform and
subjected primary rat hepatocytes to different fixed FFA concentrations with this oxygen gradient superimposed. Our results demonstrated that the largest effect of an oxygen gradient exposure on lipid accumulation is observed at the lower
FFA concentrations, resulting in zonal fat accumulation, in
line with predictions of a recent computational study.25
In the following, we show that we were able to create an
in vitro progressive NAFLD model on a single microfluidic
chip, where varying levels of fatty liver conditions were
achieved. We also used this platform to create an oxygen gradient and exposed primary hepatocytes to different FFA concentrations in this system to investigate the role of oxygen on
lipid accumulation and NAFLD progression. This progressive
disease platform can allow for dissection of NAFLD progression and most importantly can be built upon for highthroughput drug testing. Similarly, while we have limited ourselves to free fatty acid and oxygen concentrations, other effectors such as inflammatory cues can also be superimposed
onto the existing conditions to recapitulate an even wider
spectrum of conditions in NAFLD and its further progression.

Results
Primary hepatocyte cultures perfused with a free fatty acid
(FFA) gradient
The majority of in vitro NAFLD platforms utilize free fatty
acid (FFA) supplemented media to induce hepatic
steatosis.13–15,17,18 Here, we treated rat primary hepatocytes
with linoleic acid (LA) to induce lipid accumulation. As demonstrated in Fig. 1, an FFA gradient of 0–2 mM was generated
by supplying media with 0 mM and 2 mM LA to the inlet on
the left and on the right of the gradient generator, respectively. We decided on the FFA concentrations based on data
from clinical studies, which showed that test subjects with

Fig. 1 Establishment of the progressive NAFLD model. (A) Cartoon
demonstration of lipid accumulation in hepatocytes during NAFLD
progression, which can be achieved in vitro by an increasing supply of
free fatty acid (FFA) concentration. (B) Visual demonstration of gradient
generation in the microfluidic device. Experimental gradient was
created by supplying one inlet with regular media (0 mM linoleic acid,
LA) and the other with 2 mM LA. The inlets were connected to two
syringes controlled by a single pump. These media were mixed in the
gradient generator and were fed to each channel in the cell culture
chambers labelled 1–5. Artificial food colouring was added to the
media in the two syringes in this image to demonstrate formation of
gradients.

healthy liver had an approximate FFA concentration of 0.7
mM ± 0.4 mM whereas NAFLD patients had an approximate
FFA concentration of 1.1 mM ± 0.6 mM,29 and in some cases
as high as 3 mM.30 Following the exposure of primary hepatocytes to 0–2 mM LA gradient for 24 hours, the cells were either stained for quantification of viability and fat storage or
lysed to assess the changes in gene expression levels.

Cell viability and lipid accumulation following FFA gradient
exposure
We measured the amount of stored lipids in hepatocytes
in each channel of the microfluidic device following the
FFA exposure. Representative channel pictures are shown in
Fig. 2A, where we observed an increase in the Oil-Red-O stain
along the FFA gradient. Bright-field images of channels also
indicated the formation of lipid vesicles inside the cell cytoplasm, especially in channels 4 and 5. We performed image
quantification of lipid staining by assigning the absolute
values of channel 1 and channel 5 as 0% and 100%, respectively; and by normalizing the absolute values of the other
channels accordingly. As shown in Fig. 2B, the lipid accumu-

lation in hepatocytes in channels 2, 3 and 4 was 19%, 48%
and 85%, respectively. Cell viability of hepatocytes in each
channel was determined via a live/dead cell assay kit. The viability did not change significantly across the FFA gradient
and was within the range of 84–87% (Fig. 2C), indicating that
the explored FFA range was not toxic to hepatocytes. Representative channel pictures of live/dead staining (bright-field,
Hoechst 33342 and ethidium homodimer-1 images) are
shown in Fig. S1.†

Gene expression profile of NAFLD/lipid metabolism markers
upon FFA gradient exposure
In order to explore the progression of NAFLD at the transcriptional level, we investigated the gene expression levels of several NAFLD markers and genes associated with lipid metabolism in primary hepatocytes upon exposure to an FFA
gradient of 0–2 mM. As demonstrated in Fig. 3, the expression levels of several markers gradually increased along the
FFA gradient. The expression levels of lipogenesis markers
acetyl-CoA carboxylase α (ACACA) and fatty acid synthase
(FASN) increased by up to 2.3 and 2.8-fold, respectively. Acyl-

Fig. 2 Lipid accumulation and cell viability upon linoleic acid (LA) gradient exposure. (A) Representative images of channels stained with Oil-RedO (top panel: control group with no LA treatment; middle panel: hepatocytes subjected to 0–2 mM LA). Bright-field images of the 0–2 mM LA device are shown in the bottom panel where lipid droplets can be seen in the magnified image of hepatocytes in channel 5. (B) Quantified lipid accumulation in the 0–2 mM LA device. (C) Percentage cell viability in each channel was assessed via a live-dead kit following the 24 h perfusion with
0–2 mM LA gradient. All data are presented as mean ± SEM.

Fig. 3 Fold gene expression changes of NAFLD pathogenesis and lipid metabolism markers. The changes in the mRNA levels of the following
markers were quantified via quantitative real-time PCR: acetyl-CoA carboxylase α (ACACA), acyl-CoA synthetase long chain family member 4
(ACSL4), carbohydrate responsive element-binding protein (ChREBP), elongation of long-chain fatty acids family member 6 (ELOVL6), fatty acid
synthase (FASN), fatty acid transporter protein 5 (FATP5), glucokinase (GCK) and efflux transport multidrug resistance-associated protein 3 (MRP3).
The data are presented as mean ± SEM. N ≥ 3, * = p < 0.05, ** = p < 0.01, *** = p < 0.005.

CoA synthetase long chain family member 4 (ACSL4) expression increased by up to 2.2-fold (in channel 5) whereas the
elongation of long-chain fatty acids family member 6
(ELOVL6) expression increased by up to 2.6-fold. For all these
targets, the changes in fold expression in channels 4 and 5
were statistically significant compared to channel 1 (Fig. 3
and S2†).
The expression levels of fatty acid transporter protein 5
(FATP5), responsible for FFA uptake, increased with higher
linoleic acid supplementation as well, although a statistically
significant change in fold expression was only observed in
cells of channel 5. Glucokinase (GCK) expression was increased by up to 5-fold, which is associated with triglyceride
formation and is an activator of hepatic lipogenesis; and the
efflux transport multidrug resistance-associated protein 3
(MRP3) expression increased by up to 3.4-fold upon FFA treatment. For both targets, the changes in expression levels were
significant in channels 4 and 5, compared to the first channel
of devices. All expression data were normalized to the first
channel. Lastly, the expression of carbohydrate responsive
element-binding protein (ChREBP), a transcriptional factor
contributing to the regulation of triglyceride synthesis, was
found to be significantly upregulated by 2.1-fold in channel 5.

13 μM cobalt in one inlet and regular culture media with no
sulfite or cobalt in the other inlet as demonstrated in Fig. 4A.
Consequently, we generated an oxygen gradient of 11.2 ± 0.8–
6.9 ± 0.7% inside the device channels as measured by the
VisiSens oxygen detection system (Fig. 4B). This established
oxygen concentration range is closer to the physiological oxygen gradient of 3.9–8.6% along the liver sinusoid,31,32 compared to the conventional open-air cell cultures at the atmospheric oxygen pressure and concentration of 20%.
We supplemented this media with different FFA concentrations (0.25 mM, 0.5 mM, and 1 mM LA) to investigate the
effect of oxygen deprivation on lipid accumulation at different levels of fatty acid availability (Fig. 5A and B). Following
the perfusion of devices for 24 hours, we quantified the lipid
accumulation via Oil-Red-O staining. Representative channel
pictures of hepatocytes subjected to the oxygen gradient are
shown in Fig. 5A. Additional Oil-Red-O images are also given
in Fig. S3,† where we subjected hepatocytes to different FFA
and sulfite/cobalt concentrations in well plates. During image

Effect of oxygen deprivation on lipid accumulation
Following the establishment of a lipid accumulation gradient
in our platform accompanied by an increase in several NAFLD
markers, we used this device to investigate the effect of oxygen deprivation on fat storage. A spatially heterogenous lipid
accumulation is observed in the liver due to metabolic zonation; and insufficient oxygen supply is usually associated with
NAFLD and steatosis development.26 Accordingly, we created
a chemically induced oxygen gradient via oxygen quenching
by using culture media supplemented with 0.13% sulfite and

Fig. 4 Oxygen gradient generation in the microfluidic device. (A)
Representative oxygen gradient profile measured by the Visisens
oxygen detection system. Inlet 1: 0% sulfite/0 μM cobalt and inlet 2:
0.13% sulfite/13 μM cobalt. (B) The descending oxygen levels along the
culture chamber with increasing sulfite/cobalt concentrations. An
oxygen gradient of 11.2–6.9% was generated.

Fig. 5 Effect of oxygen deprivation on lipid accumulation. (A) Representative channel pictures of hepatocytes subjected to an oxygen gradient of
11.2–6.9%, top panel: no additional linoleic acid (LA) supplementation, bottom panel: in the presence of 0.25 mM LA supplementation. (B) Cartoon
representation of the hypothesized effect of oxygen deprivation on lipid accumulation (represented by beige ellipses). (C) Quantification of
percent lipid accumulation in oxygen gradient devices supplemented with varying levels of LA. The absolute values of each channel were
normalized to the 0–2 mM LA control device, of which channels 1 and 5 were assigned to 0% and 100%, respectively. The solid lines for all three
groups represent the linear regression analyses which are used to determine the slope for each group and thus the magnitude of the effects of the
oxygen gradient. The data are presented as mean ± SEM.

quantification of device experiments, we normalized the absolute values of each channel to 0–2 mM LA in the control
device, of which channels 1 and 5 were assigned to 0% and
100%, respectively. The obtained values were fit via linear regression as shown in Fig. 5C. The resulting slopes, which indicate the relative effect of oxygen deprivation on zonal lipid
accumulation, were 7.8, 6.4 and 3.7 for oxygen gradient devices supplemented with 0.25 mM, 0.5 mM, and 1 mM
linoleic acid, respectively.
This data suggested that the difference in the lipid content of hepatocytes in channels 1 and 5 was more drastic for
the device supplemented with the lowest FFA. Thus, the oxygen gradient had the highest effect on fat storage at the lowest FFA supplementation, which is in good agreement with
the results of a recent computational work,25 where the authors concluded that the ratio of accumulated TG concentration in the pericentral region (low oxygen) over the periportal
region (high oxygen) is higher at lower FFA concentrations in
blood.

Discussion
NAFLD is a progressive disease, both in pathogenesis and
with respect to the native zonal heterogeneity across the liver
tissue. As such, it is important for an in vitro disease model

to capture these characteristics to reliably investigate both
the disease itself and effective treatment options. Here, we
established a progressive NAFLD on a chip platform by perfusing rat primary hepatocytes with a free fatty acid gradient
of 0–2 mM to reflect the progressive nature of the disease
(Fig. 1).
Despite the generation of a linear linoleic acid gradient,
the quantification of fat storage in hepatocytes in different
channels indicated a slightly non-linear response showing a
saturation towards channels 4 and 5, as demonstrated in
Fig. 2B. There has been a debate on the exact mechanism of
FFA uptake, where two mechanisms are considered: simple
diffusion of FFAs across the cell membrane and transportmediated uptake of FFAs.33 For the latter, FFA transport follows Michaelis–Menten kinetics, where its uptake approaches
a steady state as the FFA concentration increases outside the
cell.34 Our results did not indicate a clear linear lipid accumulation, which would have been expected in the case of
simple diffusion. The shape of the second-half of the lipid accumulation graph (channels 3–5, Fig. 2B) resembles the beginning of a Michaelis–Menten type of saturation curve, characteristic of a transporter-mediated mechanism. As such,
higher LA concentrations resulted in a saturation of the
FFA uptake. This could imply that FFA intake was
transporter-mediated in a non-linear fashion, rather than

through simple diffusion, for higher LA concentrations (>1
mM). We studied the regulation of a long chain FFA transporter, FATP5, for further insight into the mechanism of LA
uptake. The expression level of this transporter was significantly upregulated in channel 5, suggesting its involvement
in the hepatic uptake of LA and upholds the idea of a transporter mediated uptake mechanism. It is important to note
that this does not rule out the possibility of simple diffusion
occurring simultaneously, as suggested by others.35
In addition to lipid accumulation, we also investigated the
changes in expression levels of several NAFLD markers and
lipid metabolism influencers upon exposure to the
established FFA gradient (Fig. 3). ACSL family members catalyze the initial step of FFA activation and ACSL4 has a high
affinity for polyunsaturated fatty acids such as linoleic acid.36
A strong correlation has been shown between NAFLD progression and ACSL4 overexpression. A 2.8-fold increase in its
mRNA levels was observed in the liver of NAFLD patients and
the expression levels of ACSL4 were also increased in hepatocellular carcinoma.37,38 In agreement with these findings, we
observed an up to 2.2-fold increase in our gradient model.
FATP5 is a FATP family member only expressed in the liver
and is responsible for FFA transport across the cell membrane as discussed above.39 It is commonly used as an NAFLD
marker and FATP5 knockdown in mice resulted in decreased
lipid accumulation.40 We observed an up to 1.9-fold increase
in the expression levels of this transporter protein. Member 6
of the ELOVL family regulates FFA composition and was
shown to play a role in insulin resistance and liver fibrosis in
NAFLD patients.41 A 3-fold increase in its mRNA levels was
also observed in mice fed a high fat diet.42 Similarly, we observed a gradual increase to up to 2.6-fold in our NAFLD
platform.
ChREBP is a transcription factor promoting transcription
of lipogenic genes, including ACACA and FASN, and contributes to TG synthesis by stimulating pyruvate kinase expression.43,44 We observed a 2.1-fold increase in its mRNA levels
in hepatocytes in channel 5, which were subjected to 2 mM
FFA. More recently, NAFLD has been associated with increased expression of other genes involved in de novo lipogenesis, such as ACACA and FASN, which are considered to
be new targets for NAFLD treatment and diagnostic markers
for NAFLD.45 In our microfluidic platform, we observed a
gradual increase in the expression levels of ACACA and FASN
(up to 2.3 and 2.8-fold, respectively), suggesting a change in
the lipogenesis metabolism of hepatocytes subjected to the
FFA gradient.
Liver biopsies from patients showed that mRNA expression of GCK, another activator of hepatic lipogenesis, was
positively correlated with accumulated TG content in the
liver.46 Similar to this in vivo observation, we measured a
gradual increase in GCK mRNA levels upon administration of
a 0–2 mM LA gradient. In channel 5, where hepatocytes had
the highest lipid accumulation, we detected a 5-fold
upregulation. Another pathogenesis marker in NAFLD is the
dysregulation of bile acid synthesis and metabolism. MRP3

contributes to the transport of biliary excretion and was
shown to get upregulated in both expression and activity in
NAFLD patients as well as animal models.47,48 In mice with
hepatic steatosis, the mRNA levels of MRP3 increased by 3.3fold, compared to wild-type animals.49 Comparable to these
results, we observed an increase of up-to 3.4-fold in MRP3 expression levels in rat primary hepatocytes.
We note that some of the studied genes respond to the
FFA gradients in a linear fashion while the others do not.
This supports the notion that FFAs activate different transcription factors that then modulate the expression of the
downstream genes through different pathways.50 Gene regulation can further be modulated by other factors such as the
specific promoter region of each gene and their location in
the genome. We posit that our gradient platform is suitable to study such dose and time response relationships
between the FFAs and these downstream genes. A higher
throughput model with more conditions than 5 chambers
can be used to capture the complete range of the expected
sigmoidal response curve.
We also investigated the effect of oxygen on lipid accumulation at different fixed concentrations of FFA supplementation to demonstrate the prowess of our platform and to confirm recent in vivo and computational studies with intriguing
insights. The in vivo studies on livers of mice fed with a
steatosis-inducing diet revealed that lipid accumulation differs along different zones of the liver.51 Histology analysis indicated that hepatocytes in the pericentral zone accumulate
more lipid droplets compared to those in the periportal zone,
paralleling the oxygen gradients (higher and lower oxygen
levels in the periportal and pericentral zones, respectively)
across the sinusoid.1 A recent computational study investigated the influence of the oxygen gradient and plasma FFA
gradient on the rate of fat accumulation in hepatocytes along
the liver sinusoid.25 The authors modeled the lipid metabolism under a high-fat diet and analyzed the FFA oxidation
rate and TG accumulation. They highlighted oxygen as a major contributor to zonal fat accumulation due to its critical
role in mitochondrial FA oxidation. In addition, their results
showed that the pericentral steatosis dominance decreases
with increasing FFA supplementation (over a range of 0–2000
μmol min−1 FFA in blood). This indicates that the oxygen gradient driven difference in TG accumulation – between the
periportal and pericentral compartments – disappears with
increasing FFA concentrations. This hypothesis was further
supported by an in vivo study which showed a gradual loss of
fat zonation in overfed mice,21 but was yet to be tested
in vitro.
We have previously performed hypoxia studies, where we
generated chemically induced oxygen gradients of 6.9–
0.3%.20 Here, we generated a more physiologically relevant
oxygen gradient of 11.2–6.9% in a similar fashion (Fig. 4). After subjecting rat hepatocytes to this established gradient for
24 h, we quantified the fat storage and observed higher lipid
accumulation in the 5th channel, successfully reproducing
lipid zonation in vitro for the very first time. We then

performed experiments in the presence of 0.25, 0.5 and 1
mM LA supplementation to assess the lipid zonation at different levels of FFA consumption. Our results showed that
the difference of lipid accumulation in channels 1 and 5 decreased with increasing FFA concentrations (Fig. 5), in agreement with the computational25 and in vivo studies.21 This
loss of zonation is attributed to the saturation in lipid accumulation at higher FFA exposure, whereby lipid accumulation
increases in all channels (zones) attenuating the differences
in oxygen concentration.

sponding experimental gradient for 24 h as described in the
following “Generation of the fatty acid gradient” and “Generation of the oxygen gradient” sections. The basal experimental media consisted of William's medium E supplemented
with 200 U mL−1 penicillin, 200 μg mL−1 streptomycin, and
5% bovine serum albumin (BSA). For well plate experiments,
approximately 6 × 105 hepatocytes were seeded on collagen
coated 12 well plates (Corning, New York, NY, USA). The cells
were incubated for 30 min at 37 °C and then washed with
fresh DMEM media.

Experimental

Generation of the fatty acid gradient

Microfluidic device design and fabrication

The cells were exposed to a gradient of 0–2 mM linoleic acid
(Sigma-Aldrich) in basal experimental media. The linoleic
acid (LA) was dissolved in dimethyl sulfoxide (DMSO) at 1 g
mL−1 and a 30 mM stock solution was prepared in the basal
experimental media. This solution was used to prepare the 2
mM treatment solution. After 20–24 h of culture stabilization
following cell seeding, the corresponding minimum (0 mM
LA) and maximum (2 mM LA) media were loaded into two syringes and were connected to the two inlets of the gradient
generator, which exposes the cell chamber to the established
gradient. The syringes were attached to a syringe pump (Harvard Apparatus, Holliston, MA, USA), which perfused the media at 120 μL h−1 for 24 h inside an incubator at 37 °C in
10% CO2.

The microfluidic devices (Fig. 1B) are fabricated via soft
lithography and based on the Metabolic Patterning on-a-Chip
(MPOC) design.19 Briefly, the system consists of a gradient
generator connected to a cell culture chamber area of 17
mm2 (10 mm × 1.7 mm) and a height of 200 μm. The polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, Midland,
MI) polymer solution was prepared via mixing the elastomer
and the curing agent at a 10 : 1 ratio, which was then poured
over a SU-8 negative pattern with the microfluidic design on
a silicon wafer. The bubbles were removed using a vacuum
chamber for 30 min, and then the mold was cured at 65 °C
for 24 h. Subsequently, the PDMS was peeled-off from the wafer, the individual device molds were cut off, and the inlet
and outlet ports were punched out with a 1.5 mm biopsy
puncher. The PDMS molds were bonded to glass microscope
slides (75 × 25 mm, Thermo Fisher Scientific, Grand Island,
NY, USA) via oxygen plasma treatment aligning the cell culture outlets to the edge of the glass slide to allow media outflow. For gene expression assays, an alternative design was
used, which contains four physical barriers dividing the cell
culture chamber into five distinct channels. This allows for
sectional cell lysis and collection within the microfluidic
gradient.
Rat primary hepatocyte culture
Rat primary hepatocytes were isolated from female Lewis rats
by the Cell Resource Core at the Massachusetts General Hospital (according to the protocol #2011 N000111 approved by
the institutional Animal Care and Use Committee). The cell
culture chambers of the microfluidic devices were coated
with a 50 μg mL−1 fibronectin (Sigma-Aldrich) solution in
phosphate buffered saline (PBS). Approximately 5 × 104 hepatocytes (with 90–95% viability) were injected into the cell
chamber, incubated for 30 min at 37 °C at 10% CO2 and then
washed with fresh media. The cells were seeded and
maintained for the first 24 h in Dulbecco's modified eagle's
medium (DMEM, Life Technologies, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich), 0.5 U mL−1 insulin, 7 ng mL−1 glucagon, 20 ng mL−1
epidermal growth factor, 7.5 μg mL−1 hydrocortisone, 200 U
mL−1 penicillin, 200 μg mL−1 streptomycin, and 50 μg mL−1
gentamycin. After 24 h, the cells were treated with the corre-

Generation of the oxygen gradient
An oxygen gradient was generated using sodium sulfite and
cobalt nitrate, a commonly employed approach for oxygen removal and depletion.20,52 The oxygen scavenger solution was
prepared with 0.13% (w/v) sodium sulfite and 13 μM cobalt
nitrate in basal experimental medium. 20–24 hours after cell
seeding, media with and without oxygen scavengers were
loaded into 3 mL syringes individually and connected to the
gradient generator of the microfluidic device. The devices
were perfused at 120 μL h−1 for 24 h at 37 °C in 10% CO2.
For oxygen measurement in the microfluidic device, the
VisiSens system with a VisiSens 2D sensor film (PreSens/TD
system GmbH, Germany) was used according to the manufacturer's instructions. The VisiSens sensor film was adhered to
the glass microscope slide via super glue. The device was attached onto the VisiSens sensor film after oxygen plasma
treatment. The oxygen level in the microfluidic device was
detected via the VisiSens system with a modular detector unit
for 2D read-out of fluorescent oxygen sensor foils. The images were visualized by VisiSens AnalytiCal 1 software,
followed by the quantification of the oxygen profile through
ImageJ software (NIH, Bethesda, MD, USA).
Oil-Red-O Staining
Following experimental treatment, cell culture media was removed, and the cells were washed with PBS and fixed with 4%
paraformaldehyde (Santa Cruz Biotechnology, Dallas, TX,
USA) in PBS for 15 min. For the microfluidic devices, the

PDMS chip was removed following the fixation, leaving only
the fixed cells on the glass slide. The cells were washed with
diH2O three times and then stained with a solution of 60%
Oil Red O (ScienCell, Carlsbad, CA, USA) in diH2O for 15 min.
The cells were washed three more times with diH2O. Colored
bright field images were taken using a Nikon Diaphot TMD
inverted microscope. Ten consecutive pictures were taken for
each microfluidic device, spanning the entire cell culture
chamber. For well plate experiments, 3–5 representative pictures were taken in each well. All image quantification was
processed with ImageJ (NIH, Bethesda, MD, USA). The pictures were converted to grey-scale (using the split channel
function in ImageJ (NIH, Bethesda, MD, USA)) and the average intensities of each picture was obtained. The values were
normalized to the minimum and maximum of the 0–2 mM LA
device to re-scale the values into a percentage scale.
Cell viability assay
The microfluidic device was washed with PBS to remove cell
culture media. The cells were stained with 1 : 1000 Hoechst
33342 nuclear dye (Thermo Fisher Scientific) and ethidium
homodimer-1 (Thermo Fisher Scientific) in PBS for 15 min at
37 °C according to the manufacturer's instructions. The cells
were washed with PBS and fluorescent images were obtained
using the EVOS fluorescence microscope (Thermo Fisher Scientific), spanning the whole length of the cell culture chamber.
Using ImageJ, the pictures were converted to grey-scale. The
threshold and particle analysis built-in tools were used to
count the total number of nuclei from the Hoechst 33342 fluorescence and the dead nuclei from the ethidium homodimer-1
fluorescence. The viability was represented as the ratio of dead
nuclei subtracted from the total number of nuclei to the total
number of nuclei present in each microfluidic channel.
RNA isolation and RT-PCR analysis
After inducing progressive steatosis with a gradient of linoleic
acid, the sectioned microfluidic devices were perfused with
lysis buffer (Zymo Research, Irvine, CA, USA) and the lysates
from each section were collected in separate tubes. RNA was
extracted and purified with the quick-RNA microprep kit
(Zymo Research) according to the manufacturer's instructions. A total of 10–20 ng of RNA was reverse transcribed with
cDNA synthesis kit (iScript, Bio-rad, Portland, ME, USA)
according to the manufacturer's instructions. Quantitative
PCR was performed in a ViiA 7 Real-time PCR system
(Thermo Fisher Scientific) using power SYBR Green PCR master mix kit (Thermo Fisher Scientific) according to the manufacturer's instructions. The PCR primers for each target are
given in ESI† Table S1. The relative mRNA expression was
quantified using the comparative Ct (ΔΔCt) method on the
ViiA 7 Real-time PCR system.
Statistical analysis
All quantitative data are presented as the mean ± standard error of the mean (SEM) from at least three devices seeded with

primary rat hepatocytes from different isolations. GraphPad
Prism software (Graphpad Software Inc., San Diego, CA) was
used for statistical analysis of qPCR results. Statistical significance of the results was assessed using one-way ANOVA
where channels 2–5 were compared to channel 1. P-values
less than 0.05 were considered statistically significant.

Conclusions
In this study, we established a microfluidic progressive
NAFLD platform to capture the wide spectrum of NAFLD on a
single integrated chip. We subjected rat primary hepatocytes
to a linoleic acid gradient of 0–2 mM and observed an increasing lipid accumulation across the length of the cell culture chamber, while the cell viability did not vary significantly across the five channels of the device. We also
investigated the change in expression levels of several hepatic
markers of lipid metabolism including fatty acid transporter
FATP5, which showed a significant increase in channel 5
only. The expression levels of other NAFLD markers, such as
ACSL4, were also significantly upregulated, mostly in channels 4 and 5, where the hepatocytes were treated with >1
mM FFA. Finally, we investigated the role of oxygen deprivation in lipid accumulation and found that the difference in
lipid accumulation among hepatocytes subjected to an oxygen gradient of 11.2–6.9% decreased gradually upon an increase in FFA supplementation, in agreement with the results
of recently published computational and in vivo studies. To
our knowledge, this is the first in vitro demonstration of lipid
zonation.
The developed model can either simulate the progression
of the disease spectrum or aid in dissecting the effects of spatial heterogeneity during any stage of the disease. This progressive high-throughput disease model can be used for hypothesis testing about NAFLD progression and its
heterogeneity, including inflammatory cues, as well as for
compound screening and efficacy testing of drugs against
progressively severe NAFLD conditions. While we have limited the throughput of the device in this study to 5 chambers,
the extension to higher throughput models with higher number of chambers is possible. We aim to conduct such studies
of efficacy and other therapies, and higher throughput implementation of the platform in the near future.
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